Cogent Biosciences Inc logo

COGT

Cogent Biosciences Inc

$15.25

Earnings Summary

Revenue
$0Mn
Net Profits
$-30.63Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Cogent Biosciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Cogent Biosciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Cogent Biosciences Inc’s net profit fell -161.2% since last year same period to $-30.63Mn in the Q1 2022. On a quarterly growth basis, Cogent Biosciences Inc has generated -22.97% fall in its net profits since last 3-months.

Net Profit Margins:

Cogent Biosciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Cogent Biosciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cogent Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.65
EPS Estimate Current Year
-0.65

Highlights

EPS Estimate Current Quarter:

Cogent Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.65 - a -25% fall from last quarter’s estimates.

EPS Estimate Current Year:

Cogent Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.65.

Key Ratios

Key ratios of the Cogent Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.68
Return on Assets (ROA)
-0.24
Return on Equity (ROE)
-0.41
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Cogent Biosciences Inc’s earning per share (EPS) fell -100% since last year same period to -0.68 in the Q1 2022. This indicates that the Cogent Biosciences Inc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cogent Biosciences Inc’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cogent Biosciences Inc’s return on equity (ROE) stands at -0.41.

Dividend Per Share (DPS):

Cogent Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.52
-0.68
-30.77%

Company Information

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

Organisation
Cogent Biosciences Inc
Employees
15
Industry
Health Technology